Can Statins Cause Pins and Needles?

Statins can cause pins and needles, though the symptom is far less common than the muscle aches these drugs are known for. The sensation typically stems from peripheral neuropathy, a type of nerve damage affecting the hands and feet. One case-control study found that statin users had roughly four times the odds of developing unexplained polyneuropathy compared to non-users, and the risk climbed steeply with longer use.¹ The picture is messier than that single number suggests, though, because other studies have struggled to confirm such a strong link, and a surprisingly large share of side effects reported on statins turn out to be indistinguishable from placebo responses.

What Statin-Related Nerve Symptoms Feel Like

The classic complaint is tingling, numbness, or a “pins and needles” feeling in the toes or fingers that creeps upward over weeks or months. This pattern reflects damage to peripheral nerves, the long wiring that runs from the spinal cord to the extremities. Clinicians have documented cases in which statin users developed what is called small fiber neuropathy, affecting the thinnest nerve fibers responsible for pain and temperature sensing. In a case series of three patients, small fiber neuropathy appeared within a month of starting a statin, and all three recovered after the drug was stopped. When one patient was re-challenged with the same statin, both small and large fiber neuropathy returned.²

Beyond tingling, some people report burning pain, a feeling that their feet are “wrapped in cotton,” or difficulty sensing hot and cold. These symptoms can be subtle enough to dismiss as poor circulation or sleeping on a limb wrong. When the damage extends to motor nerves, weakness or clumsiness in the hands or feet can develop, though that is rarer. The key distinguishing feature is symmetry: statin-related neuropathy tends to affect both sides of the body equally, starting at the tips of the toes or fingers and gradually moving inward.

How Statins Might Damage Nerves

Statins work by blocking an enzyme involved in cholesterol production. Cholesterol gets a bad reputation in the context of heart disease, but it is a critical building block for myelin, the insulating sheath that wraps around nerve fibers and allows electrical signals to travel quickly. Animal research has shown that inhibiting cholesterol synthesis can slow down myelination of peripheral nerves, leaving axons with thinner insulation or none at all.³ Separate lab work has demonstrated that statins interfere with the signaling pathways mature oligodendrocytes use to form and maintain myelin, and that the drugs can impair remyelination even after damage has occurred.⁴

A second mechanism involves coenzyme Q10 (CoQ10), a molecule that cells rely on for energy production. Because the same enzyme statins block also feeds the pathway that makes CoQ10, statin users often have lower levels of it in their blood. In one cross-sectional study, statin users had average CoQ10 levels around 30 ng/ml compared to roughly 49 ng/ml in non-users. Among those statin users, the ones who showed nerve conduction problems had even lower CoQ10 levels, averaging about 24 ng/ml. The researchers also found that slower nerve conduction velocity in the legs correlated with lower CoQ10.⁵ This does not prove that CoQ10 depletion causes the nerve damage, but the correlation is strong enough to keep researchers interested.

Statins can also cause peripheral neuropathy or unmask a pre-existing neuromuscular junction problem that had been silent before the drug was introduced.⁶ In other words, some people who develop pins and needles on a statin may have had a nerve condition lurking below the surface that the medication pushed into noticeable territory.

Which Statins Carry More Risk

Not all statins are created equal when it comes to nerve-related side effects. The drugs fall into two broad categories based on how easily they dissolve in fat. Lipophilic (fat-soluble) statins can cross cell membranes more readily, which may give them greater access to nerve tissue. A review of adverse event reports found that the association with neuropathy was strongest for atorvastatin and fluvastatin, both of which are highly lipophilic. Lovastatin and simvastatin, which are also lipophilic but to a lesser degree, showed a weaker association. The hydrophilic statins rosuvastatin and pravastatin had a similarly modest link, and pitavastatin had no reported association with neuropathy at all.⁷

If you are on a lipophilic statin and develop tingling, your doctor may suggest switching to a hydrophilic one rather than dropping statins entirely. This preserves the cardiovascular protection while potentially sidestepping the nerve issue. It is not a guaranteed fix, but it is one of the first practical steps clinicians try.

Duration of Use Matters More Than You Might Expect

The case-control study mentioned earlier turned up a striking dose-duration relationship. Among current statin users, the odds of definite idiopathic polyneuropathy were roughly 16 times higher than in non-users. For patients who had been on statins for two or more years, the odds ratio climbed to about 26.¹ Those are attention-grabbing numbers, though it is worth noting that this study specifically looked at “idiopathic” cases where no other cause of neuropathy could be found. The absolute number of people affected was still small because idiopathic polyneuropathy itself is uncommon.

A separate study examining nerve fiber density in the skin found that cumulative statin dose correlated with reduced nerve fiber density in the thigh, though not in the calf. The correlation was modest but statistically significant, suggesting that long-term, high-dose statin exposure gradually thins out the nerve fibers in certain areas.⁸ The fact that the calf showed no change while the thigh did is puzzling and hints that the relationship between statins and nerve density is not simple or uniform.

Controlled Studies Tell a More Cautious Story

Case-control studies and adverse event reports tend to overstate rare side effects because they are specifically looking for patterns. When researchers have tried to find a statistically significant difference in neuropathy rates between statin users and non-users in more controlled settings, the results have been less dramatic. One study that tested nerve conduction in both groups found no significant difference in actual neuropathy rates across several definitions. Two specific measurements, the amplitude of the peroneal motor nerve and the sural sensory nerve, did show statistically significant differences, and one broader definition of neuropathy just missed significance.⁹ That gap between dramatic case reports and lukewarm controlled data is a recurring theme in statin research and part of why the question “can statins cause pins and needles” does not have a crisp yes-or-no answer.

The evidence sits in an awkward middle ground. There are plausible biological mechanisms. There are individual case reports that are hard to explain away, especially the ones where symptoms returned when the statin was restarted. But the controlled data does not show a large, consistent signal that statin users develop neuropathy at a clearly elevated rate. Researchers have characterized this as a real but uncommon effect that existing studies may be underpowered to capture reliably.

The Nocebo Problem

A complicating factor in all statin side-effect research is the nocebo effect, which is the tendency for people to experience symptoms they expect to experience. In a landmark crossover trial where participants randomly cycled through months of taking a statin, a placebo, and nothing at all, the average symptom intensity scores were revealing. Symptom scores during months with no tablet averaged 8.0. During statin months, the average was 16.3. But during placebo months, it was 15.4, which was not statistically different from the statin months. The nocebo ratio was 0.90, meaning about 90% of the side-effect burden people attributed to their statin could be reproduced by a sugar pill.¹⁰

This does not mean statin side effects are imaginary. But it does mean that if you read about statins causing pins and needles and then start noticing tingling in your feet, your brain may be generating or amplifying a sensation it would otherwise filter out. An analysis of adverse event reports submitted to the FDA found that subjective statin side effects were reported more often by women than by men and more often in the United States than in other countries, a pattern consistent with cultural and psychological influences on symptom perception.¹¹ None of this means you should ignore new symptoms. It means a careful diagnostic workup is more important than simply assuming the statin is the culprit.

What Happens When You Stop the Statin

If a statin is genuinely causing nerve damage, stopping the drug usually helps. A review of cases found that symptoms improved or disappeared within weeks to months after discontinuation in most patients. People who had been on the drug for a shorter time were more likely to recover completely, while longer exposure made full recovery less certain. In every documented case where the statin was resumed after improvement, symptoms came back or got worse.¹² That rechallenge pattern is some of the strongest evidence that the drug-nerve connection is real, even if population-level studies have trouble detecting it.

For muscle-related statin symptoms (which are much more common than nerve symptoms), a study tracking outcomes after statin withdrawal found that about 73% of patients had complete resolution and another 13% improved, but roughly 19% still had lingering symptoms more than 14 months later.¹³ Nerve recovery tends to follow a similar trajectory: most people get better, but some are left with residual damage, especially if they stayed on the drug for years before the problem was recognized.

The Diabetes Complication

Diabetes is the single most common cause of peripheral neuropathy worldwide, and many people who take statins have diabetes or are at high risk for it. This creates a diagnostic tangle. If you are diabetic and on a statin, how do you know which one is responsible for the tingling in your feet? In many cases, both may be contributing.

A cross-sectional study comparing people with type 1 diabetes on statins, people with type 1 diabetes not on statins, and healthy controls found that both diabetic groups had significantly worse neuropathy measures than healthy controls. However, despite the statin group being older and having diabetes for longer, most neuropathy measures were comparable between the two diabetic groups.¹⁴ The statin group did have slightly worse scores on neuropathy symptoms and disability questionnaires, but the differences were modest. The takeaway is that in diabetic patients, statins do not appear to dramatically accelerate neuropathy beyond what diabetes itself is already doing.

Interestingly, some evidence suggests statins may actually protect diabetic nerves through their anti-inflammatory properties. A systematic review noted that statins have the potential to slow the progression of diabetic peripheral neuropathy thanks to anti-inflammatory, antioxidant, and immune-modulating effects that go beyond cholesterol lowering.¹⁵ So the relationship between statins and nerves in diabetes is genuinely two-sided: the drug might harm nerves through one mechanism while protecting them through another.

What to Do If You Suspect Statin-Related Tingling

The worst thing you can do is stop your statin on your own without talking to your doctor. Statins substantially reduce the risk of heart attacks and strokes, and the neurological risk, while real, is both rarer and less immediately dangerous. Here is a sensible approach if you develop new tingling or numbness:

Document the timing: When did the symptoms start relative to beginning or changing your statin? Neuropathy that appears within weeks to months of a new prescription or a dose increase is more suspicious than tingling that has been slowly developing for years.
Rule out other causes: Diabetes, vitamin B12 deficiency, alcohol use, thyroid disorders, and carpal tunnel syndrome are all far more common causes of pins and needles than statins. Your doctor should check for these before blaming the statin.
Consider a trial off the statin: If other causes are ruled out, a monitored period off the statin (typically a few weeks to months) can clarify whether the drug is responsible. If symptoms improve and then return when the statin is restarted, that is strong evidence.
Ask about switching: Moving from a lipophilic statin like atorvastatin to a hydrophilic one like rosuvastatin or pravastatin may resolve the issue while keeping your cardiovascular protection in place.

Researchers have suggested that pharmacogenomic testing, which looks at genetic variations that affect how your body processes statins, may eventually help predict who is at risk for neuromuscular complications before they occur.⁶ That kind of personalized prescribing is still mostly a research goal rather than routine clinical practice, but it highlights the broader direction of the field.

CoQ10 Supplements and Nerve Symptoms

Because CoQ10 depletion is one of the proposed mechanisms linking statins to nerve damage, the obvious question is whether taking a CoQ10 supplement can prevent or treat the problem. The cross-sectional study that found correlations between low CoQ10 and poor nerve conduction in statin users is suggestive, but correlation is not the same as proof that supplementation helps.⁵ For muscle symptoms, CoQ10 supplementation trials have produced mixed results over the years, with some showing benefit and others showing none. For nerve symptoms specifically, there is even less clinical trial data. The supplement is generally safe and inexpensive, which is why many doctors do not object to patients trying it, but it should not be treated as a proven solution.

Niacin (vitamin B3) has also been flagged as potentially relevant. The same analysis that ranked statins by their neuropathy risk found that combining statins with niacin appeared to reduce the association with peripheral neuropathy.⁷ However, niacin supplementation itself can have side effects (flushing, liver issues at high doses), and the evidence for this particular combination is still preliminary. It is the kind of finding that deserves more research before it becomes a recommendation.

When Pins and Needles on a Statin Are Not About the Statin

Statins are prescribed overwhelmingly to people who are middle-aged or older, overweight, have high blood pressure, or have diabetes. Every one of those characteristics is independently associated with peripheral neuropathy. Age alone increases the prevalence of neuropathy substantially, and the metabolic syndrome that often accompanies high cholesterol is a neuropathy risk factor in its own right. This means the population most likely to take statins is also the population most likely to develop pins and needles from other causes entirely.

Vitamin B12 deficiency deserves special mention because metformin, a diabetes drug that is frequently co-prescribed with statins, is known to reduce B12 absorption. A person on both metformin and a statin who develops tingling in their feet may be experiencing B12-related nerve damage rather than statin-related nerve damage. The treatment for B12 deficiency is straightforward supplementation, so it is worth checking a B12 level before assuming the statin is at fault.

Carpal tunnel syndrome and other compression neuropathies can also produce pins and needles that get mistakenly attributed to medication. These conditions cause symptoms in specific distributions (the thumb and first two fingers for carpal tunnel, for instance) rather than the symmetric stocking-glove pattern typical of drug-induced neuropathy. Paying attention to where the tingling occurs can help distinguish between these possibilities before an expensive workup is needed.

1
Neurology. Statins and risk of polyneuropathy: a case-control study
2
PubMed. Statin therapy and small fibre neuropathy: a serial electrophysiological study
3
PubMed Central. Retardation of peripheral nerve myelination in mice treated with inhibitors of cholesterol biosynthesis. A quantitative electron microscopic study.
4
PubMed Central. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo
5
PubMed. Association of statin induced reduction in serum coenzyme Q10 level and conduction deficits in motor and sensory nerves: An observational cross-sectional study
6
PubMed Central. Statins Neuromuscular Adverse Effects
7
PubMed Central. Statins combined with niacin reduce the risk of peripheral neuropathy
8
PubMed Central. Association of Statins with Sensory and Autonomic Ganglionopathy
9
PubMed Central. Lipid-lowering drugs (statins) and peripheral neuropathy
10
PubMed Central. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment
11
PubMed. Examining the Nocebo Effect of Statins Through Statin Adverse Events Reported in the Food and Drug Administration Adverse Event Reporting System
12
The Lancet. Statins and peripheral neuropathy
13
PubMed. Outcomes of statin myopathy after statin withdrawal
14
PubMed Central. Statin therapy and neuropathy in type 1 diabetes: A cross-sectional study
15
PubMed. Statins and peripheral neuropathy in diabetic and non-diabetic cases: a systematic review